Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/36098
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHarrison S.J.en
dc.contributor.authorJefford M.en
dc.contributor.authorWinship I.en
dc.contributor.authorMillar J.L.en
dc.contributor.authorGiles G.G.en
dc.contributor.authorSeymour J.F.en
dc.contributor.authorMilne R.L.en
dc.contributor.authorDoo N.W.en
dc.contributor.authorWhite V.M.en
dc.contributor.authorMartin K.en
dc.contributor.authorBassett J.K.en
dc.contributor.authorPrince H.M.en
dc.date.accessioned2021-05-14T12:13:57Zen
dc.date.available2021-05-14T12:13:57Zen
dc.date.copyright2019en
dc.date.created20190717en
dc.date.issued2019-07-17en
dc.identifier.citationCancers. 11 (7) (no pagination), 2019. Article Number: 928. Date of Publication: July 2019.en
dc.identifier.issn2072-6694 (electronic)en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/36098en
dc.description.abstractIntroduction: Diffuse large B cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma for which a cure is usually the therapeutic goal of optimal treatment. Using a large population-based cohort we sought to examine the factors associated with optimal DLBCL treatment and survival. Method(s): DLBCL cases were identified through the population-based Victorian Cancer Registry, capturing new diagnoses for two time periods: 2008-2009 and 2012-2013. Treatment was pre-emptively classified as 'optimal' or 'suboptimal', according to compliance with current treatment guidelines. Univariable and multivariable logistic regression models were fitted to determine factors associated with treatment and survival. Result(s): Altogether, 1442 DLBCL cases were included. Based on multivariable analysis, delivery of optimal treatment was less likely for those aged >=80 years (p < 0.001), women (p = 0.012), those with medical comorbidity (p < 0.001), those treated in a non-metropolitan hospital (p = 0.02) and those who were ex-smokers (p = 0.02). Delivery of optimal treatment increased between 2008-2009 and the 2012-2013 (from 60% to 79%, p < 0.001). Delivery of optimal treatment was independently associated with a lower risk of death (hazard ratio (HR) = 0.60 (95% confidence interval (CI) 0.45-0.81), p = 0.001). Conclusion(s): Delivery of optimal treatment for DLBCL is associated with hospital location and category, highlighting possible demographic variation in treatment patterns. Together with an increase in the proportion of patients receiving optimal treatment in the more recent time period, this suggests that treatment decisions in DLBCL may be subject to non-clinical influences, which may have implications when evaluating equity of treatment access. The positive association with survival emphasizes the importance of delivering optimal treatment in DLBCL.Copyright © 2019 by the authors.en
dc.languageenen
dc.languageEnglishen
dc.publisherMDPI AG (Postfach, Basel CH-4005, Switzerland. E-mail: indexing@mdpi.com)en
dc.relation.ispartofCancersen
dc.titleThe use of optimal treatment for DLBCL is improving in all age groups and is a key factor in overall survival, but non-clinical factors influence treatment.en
dc.typeArticleen
dc.type.studyortrialObservational study (cohort, case-control, cross sectional or survey)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.3390/cancers11070928en
dc.publisher.placeSwitzerlanden
dc.identifier.source2002203629en
dc.identifier.institution(Doo, Martin, Bassett, Milne, Giles) Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC 3004, Australia (Doo) Concord Repatriation General Hospital, Sydney Medical School, University of Sydney, Sydney, NSW 2139, Australia (Doo) Concord Clinical School, University of Sydney, Concord, NSW 2139, Australia (White) School of Psychology, Faculty of Health, Deakin University, Geelong, VIC 3220, Australia (White) Centre for Behavioural Research in Cancer, Cancer Council Victoria, Melbourne, VIC 3004, Australia (Prince, Harrison, Seymour) Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, VIC 3000, Australia (Prince, Harrison, Jefford, Seymour) Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia (Jefford) Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia (Winship) Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, VIC 3050, Australia (Winship) Department of Medicine, The University of Melbourne, Parkville, VIC 3010, Australia (Millar) Alfred Health Radiation Oncology, Alfred and LaTrobe Regional Hospital, Melbourne, VIC 3004, Australia (Millar) School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia (Milne, Giles) Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC 3010, Australia (Milne, Giles) School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC 3800, Australiaen
dc.description.addressN.W. Doo, Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC 3004, Australia. E-mail: nicole.wongdoo@health.nsw.gov.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2019 Elsevier B.V., All rights reserved.en
dc.subect.keywordsCancer survival Chemotherapy Diffuse large B cell lymphoma Epidemiologic studies Patterns of careen
dc.identifier.authoremailDoo N.W.; nicole.wongdoo@health.nsw.gov.auen
dc.description.grantNo: EOI09_36 Organization: (VCA) *Victorian Cancer Agency* Organization No: 100008018 Country: Australiaen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeArticle-
Appears in Collections:Articles
Show simple item record

Page view(s)

24
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.